Laboratory reference testing and clinical trial services company, med fusion, has entered into a market development agreement to validate the clinical utility of Theranostics Health‘s TheraLink assays for use in patients with malignant diseases.
TheraLink assays are designed to measure the activation status of signal transduction pathways of each individual and provide personalised treatment.
Under the agreement, both the companies will work together to provide clinical validation of the TheraLink assays through clinical trials conducted by med fusion, as well as through other oncology practices.
In addition, the companies will jointly conduct promotional, marketing and sales-related efforts, technology integration, as well as other activities aimed at the clinical services, clinical trials, diagnostic, theranostic and personalised healthcare markets.
med fusion chief medical officer Dr Thomas Lohmann said; "This Market Development Agreement with Theranostics Health will advance med fusion’s objective to be on the leading edge of technology and help ensure that we are supporting physicians and patients with the most advanced molecular technologies."
med fusion chief executive officer Keith Laughman said; "The alliance further supports med fusion’s current and future collaborations as it continues to execute its targeted diagnostics initiatives."
Theranostics Health president and CEO Glenn Hoke said the company is looking forward to supporting med fusion’s patient care goals.
"This agreement will allow med fusion to deliver critical information to doctors by providing a molecular snapshot of their patient’s tumor, helping doctors provide their patients with the right therapy and ensuring that patients receive the best care possible," Hoke said.